For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Tafinlar® (dabrafenib) + Mekinist® (trametinib) combines a BRAF inhibitor with a MEK inhibitor1

Tafinlar + Mekinist inhibits 2 points in the MAPK pathway, which is constitutively activated in BRAF V600–mutated melanoma1

Tafinlar® (dabrafenib) + Mekinist® (trametinib) BRAF mutated melanoma

  • Blocking MEK, in addition to BRAF, is thought to:
    • Reduce the risk of treatment resistance2
    • Decrease the incidence of some toxicities that may occur with BRAF inhibitor monotherapy (eg, secondary neoplasms); however, increases in other types of toxicities have been seen when Tafinlar and Mekinist are used in combination1,2

ERK, extracellular signal–regulated kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase.

References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 2. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013;14(2):e60-e69.